WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences
WIRB-Copernicus Group announced that it has acquired Alliance Biosciences.
WIRB-Copernicus Group (WCG), a provider of regulatory and ethical review services for clinical research, announced that it has acquired Alliance Biosciences. Alliance Biosciences was the leading biosafety and biosecurity consulting firm in the United States and will join WCG’s biosafety division – WCG Biosafety™ – to manage the entire continuum of biosafety oversight, helping to ensure that research involving potentially hazardous agents and vectors complies with the appropriate safety and regulatory requirements from laboratory design and drug discovery through clinical testing and therapeutic application. WCG Biosafety manages more than 200 Institutional Biosafety Committees (IBCs) and has evaluated more than 140 gene transfer clinical and recombinant DNA pre-clinical research protocols to date.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
